The Next Frontier of Medicine: Tevogen Bio ($TVGN)
Вставка
- Опубліковано 8 лип 2024
- Dr. Neal Flomenberg, Chief Scientific Officer, and Dr. Lori Grosso, Clinical Development Lead, Tevogen Bio (NSDQ: TVGN), sit down with Nasdaq's Kristina Ayanian to discuss how the clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
- Наука та технологія
